title: [Anticholinergic drugs in therapy of chronic obstructive lung disease (COPD)].
abstract: Chronic obstructive pulmonary disease (COPD) is a severe respiratory disorder responsible for a significant morbidity and mortality in western societies. In the vast majority of patients, COPD is caused by tobacco smoke. Contributing factors leading to airway obstruction and lung hyperinflation in COPD differ from those observed in asthma, with a major role of hypersecretion and peripheral airway obstruction due to increased cholinergic airway smooth muscle tone. Therefore, anticholinergics are considered the firstline therapy to improve airway obstruction in COPD. In addition to effects on lung function, anticholinergics may also improve exercise tolerance, quality of life and sleep quality in these patients. When compared with other classes of bronchodilators, anticholinergics show an equal potency of bronchodilation, with a favorable safety profile. Due to their unique mechanism of action, anticholinergics can also be combined with different types of bronchodilators. Novel, long-acting anticholinergics may hold a future potential for further improvement of therapy in COPD, particularly in terms of user friendliness and compliance.
authors.affiliation: III. Medizinische Klinik, Klinikum der Johannes-Gutenberg-Universität, Mainz. k.beeh@3-med.klinik.uni-mainz.de
authors.forename: K M
authors.initials: KM
authors.lastname: Beeh
authors.forename: T
authors.initials: T
authors.lastname: Welte
authors.forename: R
authors.initials: R
authors.lastname: Buhl
mesh_terms: D000403:Airway Resistance / Q000187:drug effects; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000209:etiology
chemical_list: D018680:Cholinergic Antagonists